



Practitioner's Docket No. MPI00-368P1RM

PATENT

RECEIVED

MAY 06 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Glucksmann, Maria A., et al.  
Application No.: 09/942,374  
Filed: August 22, 2002  
For: 57242, A NOVEL HUMAN G PROTEIN-COUPLED RECEPTOR FAMILY  
MEMBER AND USES THEREFOR

Group No.: 1646

Examiner: Ulm, J. D.

Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1.  Preliminary Statements
2.  Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) (2 pages)
- ✓ 3.  Copy of International Search Report (10 pages)
4.  Copies of Listed Information Items Accompanying This Statement (11 references)

---

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10\*

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

  
Signature

Date: April 30, 2003

Diana Gentile  
(type or print name of person certifying)

Practitioner's Docket No. MPI00-368P1RM

**Preliminary Statements**

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Copies of Listed Information Items Accompanying This Statement**

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

**Fee Payment**

Applicant believes no fee is due in connection with this submission, however, in the event any fee is due, please charge Deposit Account No. 501668.

April 30, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By

  
Kerri Pollard Schray  
Registration No. 47,066  
75 Sidney Street  
Cambridge, MA 02139  
Telephone – (617) 551-3676  
Facsimile – (617) 551-8820



Practitioner's Docket No. MPI00-368P1RM

*1646 #9*  
*Dm 5-22-03*  
**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of: Glucksmann, Maria A., et al.  
Application No.: 09/942,374  
Filed: August 29, 2001  
For: 57242, A NOVEL HUMAN G PROTEIN-COUPLED RECEPTOR MEMBER AND USES THEREFOR

Group No.: 1646

Examiner: Ulm, J. D.

**Commissioner for Patents**  
Washington, D.C. 20231

**RECEIVED**  
*MAY 06 2003*

**TECH CENTER**  
*FAX 1800/2900*

**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

**OR**

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

**CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10\***

I hereby certify that, on the date shown below, this correspondence is being:

**MAILING**

deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

**37 C.F.R. SECTION 1.8(a)**

**37 C.F.R. SECTION 1.10\***

with sufficient postage as first class mail.

as "Express Mail Post Office to Addressee"  
Mailing Label No. \_\_\_\_\_

**TRANSMISSION**

transmitted by facsimile to the Patent and Trademark Office.

*Diana Gentile*  
Signature

Date: April 30, 2003

Diana Gentile  
(type or print name of person certifying)

**\*WARNING:** Each paper or fee filed by "Express Mail" **must** have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will **not** be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

**Practitioner's Docket No. MPI00-368P1RM**

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

**FEE PAYMENT**

3.  The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission, however, in the event any fee is due, please charge Deposit Account No. 501668.

April 30, 2003

MILLENNIUM PHARMACEUTICALS, INC.

  
\_\_\_\_\_  
Kerri Pollard Schray  
Registration No. 47,066  
75 Sidney Street  
Cambridge, MA 02139  
Telephone - (617) 551-3676  
Facsimile - (617) 551-8820